SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Biocon Ltd

BSE: 532523 NSE: BIOCON ISIN: INE376G01013
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Biocon Ltd belong to?
Biocon Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Biocon Ltd a good quality company?
Biocon Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Biocon Ltd undervalued or overvalued?
Biocon Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Biocon Ltd a good buy now?
Biocon Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Biocon Ltd?
Biocon Ltd revenue growth is 5.4% for FY-2025 , which is above its 5 year CAGR of 2.4% , indicating faster growth.
Q.2 Gross Profit margin of Biocon Ltd?
Biocon Ltd Gross profit margin which is the profit after deduction of direct costs, is 8.1% for FY-2025 , which is below its 5 year median of 12.1% , indicating decreasing margins.
Q.3 Operating Profit Margin of Biocon Ltd?
Biocon Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 7.31% for FY-2025 , which is in line with its 5 year median of 7.31% indicating stable margins.
Q.4 Net Profit Margin of Biocon Ltd?
Biocon Ltd Net Profit Margin is 27.17% for FY-2025 , is above with its 5 year median of 13.83%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 8.1 12.1
Operating Profit Margin 7.31 7.31
Net Profit Margin 27.17 13.83
Q.5 Return on Asset of Biocon Ltd?
Biocon Ltd Return on Asset is 4.15%, which is above its 5 year historical median of 3.39%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Biocon Ltd?
Biocon Ltd Return on equity is 5.48% for FY-2025 , which is above its historical median of 3.68%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Biocon Ltd?
Biocon Ltd Return on capital employed is 6.57% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 11.25%, indicating value preservation.
Q.8 Cash conversion cycle of Biocon Ltd?
Biocon Ltd Cash conversion cycle is 165 days, above its historical median of 154 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.15 0.18
ROE 5.48 3.68
ROCE 6.57 4.65
Cash Conversion Cycle 165 days 154 days
Q.9 Debt to Equity ratio of Biocon Ltd?
Biocon Ltd Debt-to-Equity ratio is 0.25 , which is above with the industry average of 0.13 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Biocon Ltd?
Biocon Ltd Debt to cash flow from operations is 4.6 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Biocon Ltd?
Promoters hold 44.91% of the Biocon Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Biocon Ltd vs industry peers?
Biocon Ltd revenue CAGR is 2.44% , compared to the industry median CAGR of 8.87% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,242.6 8,127.2
Gross Profit 181.7 1,337.7
Operating Profit 163 1,810
Net Profit 609 970
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.15 0.8
ROE 5.48 18.61
ROCE 6.57 17.96
Cash Conversion Cycle (days) 165.06 76

Valuation & price assessment

Q.1 Stock return of Biocon Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 14.6% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 14.6% -2.1% 16.1% 6.5%
Q.3 Valuation ratios of Biocon Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 7834.02 85.61 40.28
Price to Book 2.15 3.56 2.77
Price to Sales 24.3 20.06 2.65
EV to EBITDA 108.66 107.23 15.67

Check more companies

1. Dr. Reddys Lab
2. Lupin
3. Zydus Lifesciences
4. Mankind Pharma
5. Aurobindo Pharma
6. Alkem Laboratories
7. Glenmark Pharma
8. Laurus Labs
9. Biocon
10. Abbott India
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×